# Clinical, immunological characterisation and treatment response of patients with syndrome of undifferentiated recurrent fever in Chinese children and adolescents: a single-centre cohort study

**Authors:** Xiongbin Chen, Wenlu Xing, Yulu Li, Mengyang Yang, Zhou Shu, Huawei Mao

PMC · DOI: 10.3389/fimmu.2026.1683408 · Frontiers in Immunology · 2026-02-18

## TL;DR

This study characterizes a group of children with undiagnosed recurrent fevers, showing they have distinct symptoms and immune features compared to other fever syndromes.

## Contribution

The study provides a detailed clinical and immunological profile of SURF patients in a large Chinese cohort.

## Key findings

- SURF patients show more gastrointestinal symptoms than PFAPA patients but similar to FMF patients.
- SURF patients have lower helper T cells and higher natural killer cells compared to PFAPA patients.
- Colchicine is more commonly used in SURF patients, while PFAPA patients are more likely to receive on-demand steroids.

## Abstract

Syndrome of undifferentiated recurrent fevers (SURF) is a heterogeneous disorder characterised by recurrent fevers and autoinflammation in the absence of a confirmed molecular diagnosis of hereditary recurrent fever (HRF) and periodic fever, adenitis, pharyngitis, aphthous stomatitis (PFAPA) syndrome. The aim of this study is to characterise the clinical and immunological features of SURF patients and to analyse their cytokine signature and treatment patterns.

Between 2022 and 2024, we enrolled 191 patients who presented to Bei Jing Children’s Hospital, Department of Immunology, with the chief complaint of recurrent fever. Fifty-seven patients met the criteria for SURF, 70 met the criteria for PFAPA and 64 met the criteria for FMF. Baseline data and blood samples were collected from patients at enrolment or at routine clinical visits. Clinical and immunological characteristics and cytokine levels were analysed.

In SURF patients, gastrointestinal symptoms(abdominal pain and vomiting or diarrhoea) were more prominent than in PFAPA patients. However, the difference in gastrointestinal symptoms between SURF patients and FMF patients was not significant. Pharyngitis and cervical adenitis were both seen in SURF and PFAPA patients while the frequency was higher in PFAPA patients. Family history was significantly higher in FMF patients than in SURF patients. The family history was similar between SURF patients and PFAPA patients. Treatment patterns differ between SURF and PFAPA (or FMF) patients. On-demand steroids were more likely prescribed in PFAPA patients, while colchicine was more commonly prescribed in SURF patients. However, no statistically significant differences were found in the prescription of colchicine between SURF and FMF patients. FMF patients were more commonly prescribed on-demand steroids than SURF patients. But SURF patients were more likely prescribed NSAIDs than FMF patients. The B-cell populations and immunoglobulin (Ig) levels (IgG, IgA, IgM and IgE) were similar in both SURF and PFAPA patients (or FMF patients). The proportion of helper T cells (Th cells) (CD3+CD4+) was significantly lower in SURF patients compared to PFAPA patients. However, the proportion of natural killer cells (NK cells) (CD3-CD56+) was significantly higher in SURF patients compared to PFAPA patients. The proportion of cytotoxic T cells (CD3+CD8+) was significantly higher in FMF patients compared to SURF patients. But the proportion and absolute count of natural killer cells (NK cells) (CD3-CD56+) was significantly lower in FMF patients compared to SURF patients. Cytokine levels between SURF and PFAPA patients (or FMF patients) were similar. SURF patients tended to have higher levels of pro-inflammatory cytokines (including IL-1β, IL-6, IL-8, IL-10, TNF-α and IFN-α). Both SURF, PFAPA, and FMF patients showed favourable responses to colchicine treatment.

This study describes the clinical and immunological characteristics of a large cohort of patients with SURF. This suggests us that SURF is a heterogenous disease. However, the clinical and immunological features and treatment options of SURF patients differ from PFAPA and FMF patients.

## Linked entities

- **Proteins:** IL1B (interleukin 1 beta), IL6 (interleukin 6), CXCL8 (C-X-C motif chemokine ligand 8), IL10 (interleukin 10), TNF (tumor necrosis factor), IFN1@ (interferon, type 1, cluster)
- **Chemicals:** colchicine (PubChem CID 2833), steroids (PubChem CID 139082353)
- **Diseases:** PFAPA syndrome (MONDO:0018540), FMF (MONDO:0009572)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, MVK (mevalonate kinase) [NCBI Gene 4598] {aka LRBP, MK, MVLK, POROK3}, MEFV (MEFV innate immunity regulator, pyrin) [NCBI Gene 4210] {aka FMF, MEF, PAAND, TRIM20}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, CD27 (CD27 molecule) [NCBI Gene 939] {aka S152, S152. LPFS2, T14, TNFRSF7, Tp55}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, CASP1 (caspase 1) [NCBI Gene 834] {aka ICE, IL1BC, P45}, IGHE (immunoglobulin heavy constant epsilon) [NCBI Gene 3497] {aka IgE}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}
- **Diseases:** Aphthous stomatitis syndrome (MESH:D013281), Adenitis (MESH:D008199), vomiting (MESH:D014839), infectious disease (MESH:D003141), Periodic Fever (MESH:D056660), Fever (MESH:D005334), AIDs (MESH:D018467), fatigue (MESH:D005221), chest pain (MESH:D002637), oral aphthosis (MESH:D020820), constipation (MESH:D003248), diarrhoea (MESH:D003967), FMF (MESH:D010505), Rash (MESH:D005076), febrile (MESH:D000071072), autoimmune diseases (MESH:D001327), nausea (MESH:D009325), abdominal pain (MESH:D015746), arthralgia (MESH:D018771), dizziness (MESH:D004244), infections (MESH:D007239), malignancy (MESH:D009369), adenopathy (MESH:D000072281), renal amyloidosis (MESH:C538249), Pharyngitis (MESH:D010612), immunodeficiency (MESH:D007153), neutropenia (MESH:D009503), arthritis (MESH:D001168), Inflammation (MESH:D007249), Gastrointestinal symptoms (MESH:D012817), upper respiratory tract infection (MESH:D012141)
- **Chemicals:** PBS (MESH:D007854), Colchicine (MESH:D003078), sodium heparin (MESH:D006493), Thalidomide (MESH:D013792), steroids (MESH:D013256)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957144/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12957144/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957144/full.md

---
Source: https://tomesphere.com/paper/PMC12957144